<DOC>
	<DOCNO>NCT00570180</DOCNO>
	<brief_summary>Given disappointing result routine ASCT ( 4 ; 14 ) patient , propose open label phase II study bortezomib along dexamethasone pegylated liposomal doxorubicin ( Doxil/Caelyx ) , refer DBd regimen , 4 cycle , follow post-induction therapy cyclophosphamide + bortezomib + prednisone ( refer CyBorP regimen ) 8 cycle . Since patient ( 4 ; 14 ) remain high risk relapse , maintenance therapy dexamethasone weekly give disease progression .</brief_summary>
	<brief_title>Combination Bortezomib-containing Regimens Newly Diagnosed Patients With ( 4 ; 14 ) Positive Multiple Myeloma</brief_title>
	<detailed_description>PROTOCOL SYNOPSIS A . TITLE : An Open-Label Phase II Study Efficacy Combination Bortezomib-containing Regimens Treatment newly diagnose patient ( 4 ; 14 ) positive Multiple Myeloma . B . RATIONALE : Between 15 20 % myeloma patient exhibit ( 4 ; 14 ) , result translocation receptor tyrosine kinase ( TK ) fibroblast growth factor receptor 3 ( FGFR3 ) chromosome 4 Immunoglobulin H ( IgH ) locus . The presence ( 4 ; 14 ) appear confer extremely poor prognosis . Patients abnormality experience prolonged remission single autologous stem cell transplant ( ASCT ) use high-dose melphalan , optimal therapy group yet define . Specifically , data Princess Margaret Hospital Mayo Clinic indicate median progression-free survival ( PFS ) 8 month overall survival 18-22 month ASCT . Unpublished data French Francophone Myeloma Intergroup ( IFM ) study suggest tandem transplant may improve result modestly , outcome still inferior compare cytogenetic subgroup . Initial unpublished observation suggest ( 4 ; 14 ) patient relapsed/refractory disease uniquely sensitive new agent bortezomib . More recent information large number patient indicate response single agent bortezomib see 50-65 % ( 4 ; 14 ) patient ; duration response similar see subset , i.e . range 5-7 month . Combinations bortezomib agent doxorubicin , pegylated liposomal doxorubicin , thalidomide , cyclophosphamide , melphalan , thalidomide corticosteroid evaluate number clinical study recurrent myeloma , response rate ( RR ) appear improve compare single agent bortezomib , toxicity acceptable . In newly diagnose myeloma patient , combination vincristine , doxorubicin , dexamethasone ( VAD ) thalidomide + dexamethasone often utilized ASCT . A study Hussein et al . substitute pegylated liposomal doxorubicin conventional formulation doxorubicin note similar response rate less grade 3/4 neutropenia , alopecia sepsis ; addition , patient necessarily require central venous catheter . More recently , Cavenagh et al . report remarkable activity so-called PAD regimen bortezomib , doxorubicin dexamethasone , combine Complete Remission ( CR ) + Partial Response ( PR ) rate 67 % follow 1 cycle , 93 % 4 cycle , impairment ability collect blood stem cell ASCT . Preliminary data ongoing Canadian phase II study Doxil/Caelyx + Bortezomib + Dexamethasone ( DBd ) , pegylated liposomal doxorubin , bortezomib dexamethasone combine , produce encouraging result date minimal toxicity . In study , DBd therapy give 4 cycle ASCT independently cytogenetic classification . Given disappointing result routine ASCT ( 4 ; 14 ) patient , propose open label phase II study bortezomib along dexamethasone pegylated liposomal doxorubicin ( Doxil/Caelyx ) , refer DBd regimen , 4 cycle , follow post-induction therapy cyclophosphamide + bortezomib + prednisone ( refer CyBorP regimen ) 8 cycle . Since patient ( 4 ; 14 ) remain high risk relapse , maintenance therapy dexamethasone weekly give disease progression . This approach test hypothesis bortezomib-based therapy improve outcome newly diagnose ( 4 ; 14 ) multiple myeloma patient . C. OBJECTIVES OF THE STUDY : To evaluate efficacy DBd regimen give induction therapy , follow post-induction therapy CyBorP maintenance therapy dexamethasone ( 4 ; 14 ) positive multiple myeloma ( MM ) patient . Primary Objectives - To determine time progression ( TTP ) treatment regimen . Secondary Endpoints - To determine objective response rate follow DBd induction therapy - To determine duration response follow DBd induction therapy - To determine objective response rate follow CyBorP post-induction therapy - To determine duration response follow CyBorP post-induction therapy - To determine PFS - To determine overall survival - To determine safety profile regimen - To examine ability bortezomib base regimen repress FGFR3 signal D. STUDY DESIGN : This open-label , Phase II study induction therapy bortezomib , pegylated liposomal doxorubicin ( Doxil/Caelyx ) dexamethasone initial therapy patient ( 4 ; 14 ) . Each 21 day-cycle consist bortezomib 1.3 mg/m2 ( give I.V . bolus Days 1 , 4 , 8 , 11 ) follow 10-day rest period ( Days 12 21 ) . DOXIL/CAELYX 30 mg/m2 give bortezomib least 1-hour I.V . infusion Day 4 21-day cycle . Dexamethasone 40 mg PO give day 1-4 , day 8-11 day 15-18 first cycle . For subsequent 3 cycle , dexamethasone 40 mg PO give day 1-4 day 11-14 . Patients experience disease progression may undergo elective , per attend physician 's discretion , stem cell mobilization follow stem cell collection cryopreservation . Patients receive post-induction therapy cyclophosphamide + bortezomib + prednisone ( 1.5 mg/m2 bortezomib day 1 , 8 , 15 I.V . + cyclophosphamide 300 mg/m2 PO weekly + prednisone 100 mg PO alternate day ) 8 monthly 28 day cycle , follow maintenance therapy 40 mg dexamethasone weekly per month disease progression occur . E. PATIENT CHARACTERISTICS : Untreated multiple myeloma patient ( 4 ; 14 ) positive fluorescence situ hybridization ( FISH ) consider study . Exclusion criterion include inadequate liver function aspartate aminotransferase ( AST } alanine aminotransferase ( ALT ) &gt; 2.5 time upper limit normal ) , thrombocytopenia ( platelet &lt; 50 X 109/L ) , neutropenia ( absolute neutrophil count &lt; 1.0 x 109/L ) , pregnant lactate woman , woman childbearing potential ( WCBP ) use adequate contraception Left Ventricular Ejection Fraction ( LVEF ) institutional Lower Limit Normal ( LLN ) less 40 % ; whichever value high . A patient may receive 4 month anti myeloma therapy , part induction therapy , prior enrollment still consider eligible participate study , long patient 's multiple myeloma progress current regimen eligibility criterion meet . F. STATISTICAL PLAN : The TTP initiation chemotherapy patient treat ASCT subset approximately 12 month . An increase TTP 12 21 month would clinical significance . Using 80 % power detect time difference two-sided comparison patient , sample size 36 evaluable patient require . This calculation assume patient evaluate fixed time 24 month . Assuming 20 % drop-out rate , total sample size 45 patient require . G. STUDY DESIGN : It assume new regimen interest ( 4 ; 14 ) positive myeloma patient TTP time start induction therapy le 21 month . Each patient follow every month disease progression every 6 moth 5 year survival . An interim analysis also perform 12 patient complete post-induction therapy cyclophosphamide + bortezomib + prednisone ( CyBorP ) . H. PATIENT ACCRUAL AND STUDY DURATION : Patients ( 4 ; 14 ) represent 15 % myeloma patient , , accrual highly dependant number participate center . It estimate approximately 350 newly-diagnosed patient require cytogenetic screening order meet accrual target . Accrual expect complete within 48 month . Additional time require , course , allow response data mature . All patient register study account ( screen failure + enrolled patient ) . The number patient evaluable , die withdrew treatment begin specify . The distribution follow-up time described number patient lose follow-up monitored . I. EFFICACY PARAMETERS : Beginning cycle 1 , response treatment determine cycle use International Myeloma Working Group uniform response criterion multiple myeloma outline Section 11.0 . Responses assess monoclonal protein , monoclonal paraprotein ( M protein ) quantification serum 24-hour urine collection ( include immunofixation , need ) , bone marrow plasma cell , assessment lytic lesion , soft tissue plasmacytoma . For patient light chain disease non-secretory myeloma , serum sample Free Lite chain test obtain result compare level report quantified urine . J . REGISTRATION : Patients register complete eligibility enrollment checklist forward fax Multiple Myeloma Research Coordinator Princess Margaret Hospital 416-946-4419 , hour 9 4 pm Eastern Standard Time , 5 business day prior commencement cycle 1 day 1 . The research coordinator also contact phone 416 946-4627 . The checklist verify patient number assign eligible patient . K. SAMPLE PROCESSING : Centralized screen employed Princess Margaret Hospital . Following informed consent site send two fresh heparinized ( green top tube ) marrow sample ( 5cc per tube best available ) overnight courier ( see Appendix VI ship notification instruction ) t4 ; 14 screen test . Tri-color fluorescence situ hybridization ( FISH ) ( 4 ; 14 ) perform report back refer site within 5-7 working day .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients previously diagnose MM base criterion International Myeloma Working Group ( IMWG ) Patients 'measurable ' disease Age 18 year time signing Informed Consent A patient may receive 4 month anti myeloma therapy , part induction therapy , prior enrollment still consider eligible participate study , long patient 's multiple myeloma progress current regimen eligibility criterion meet . Patient ( 4 ; 14 ) positive screen assay . Concomitant therapy medication include corticosteroid ( &gt; 10 mg per day prednisone equivalent ) therapy may active myeloma prior day 1 ( exception radiation therapy induction therapy describe inclusion criterion section Peripheral neuropathy Grade 2 great . Patients evidence mucosal internal bleeding and/or refractoriness platelet transfusion ( i.e. , unable maintain platelet count 50 x 109 /L ) . Patients absolute neutrophil count ( ANC ) &lt; 1.0 x 109/L . Treatment raise ANC , granulocyte colonystimulating factor ( GCSF ) granulocytemacrophage colonystimulating factor ( GMCSF ) allow within 14 day study entry . Patients hemoglobin &lt; 80 g/L despite transfusion . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>newly diagnose</keyword>
</DOC>